Compare Adaptive Biotechnologies Corp (ADPT) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.54B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.2× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AMC | |
|---|---|---|
Market Cap | $3.33B | $1.54B |
Sector | Health | Media |
52-Week High | $22.37 | $3.54 |
52-Week Low | $10.24 | $0.95 |
Enterprise Value | $3.19B | $9.13B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AMC trades at $1.72, down 8.99% in the last session amid dilution concerns from recent equity offerings. The stock shows bearish technical signals with negative cash flows and a net loss of $632.4M in 2025. Recent news highlights summer box office strength but ongoing investor worries about share dilution and profitability. The company's debt remains high at $4.01B, though revenue reached $4.85B in 2025.
Outlook remains challenged by persistent losses and high leverage, though diversification into live events offers growth potential. Key risks include dilution from equity sales and weak cash generation. Analyst consensus is mixed with a $1.85 price target, suggesting limited upside from current levels amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
